Sepsis Test Articles & Analysis
27 news found
The company is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims more lives than any cancer. Infectious disease testing (including sepsis) is one of the ...
Sepset Biosciences is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis. ...
(NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced completion of its previously planned clinical studies for the Symphony IL-6 Test (the “Test”). Results of these studies ...
This confirms our belief that the Bluejay Symphony IL-6 Test has the potential to provide an innovative solution to the market. Bluejay continues to advance the Symphony IL-6 Test towards the Company’s anticipated marketing application with the FDA, expected by year-end ...
This user-friendly system is expected to fit into ICU/near-patient settings without the need for dedicated staff to run a test. The system has been designed to measure test analytes using whole blood. Samples are collected and loaded into proprietary, test-specific cartridges. The Symphony IL-6 Test is a development stage ...
“Data from this study published in PLOS ONE demonstrate the potential of the IntelliSep test to assist clinicians in the risk stratification and early direction of care for patients before the results of longer-lead time diagnostic tests are available. ...
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep sepsis risk stratification test towards commercial ...
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 announced today that it has entered into an endorsed company agreement with MHA Solutions, a subsidiary of the Mississippi Hospital Association (MHA), and Healthcare Providers Insurance ...
“By prioritizing the development and implementation of a specific quality measure for blood culture contamination and appropriately incentivizing the use of clinical practices and technologies that are proven to reduce (and nearly eliminate) contamination, CMS can directly and dramatically reduce the number of false positive blood tests for sepsis, one of ...
The company’s initial focus is on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Future tests will be developed to run on the company’s sample-to-answer isothermal instrument platform in under 30 ...
“With ViraBac EZ and all of our tests, we are integrating diverse patient cohorts in product development to ensure that our tests will perform in real-world practice across multiple clinical settings, from doctor’s offices and outpatient clinics to the emergency room. ...
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced that six studies, reporting zero or near-zero blood culture contamination rates and up to a 31% reduction in vancomycin days of therapy (DOT) using Steripath, were ...
Severe COVID-19 is also a form of sepsis. “In sepsis, the body’s immune system becomes dysregulated and starts to damage the patient directly. ...
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the expansion of its senior leadership team with the addition of Patrick O’Malley as Chief Financial Officer. ...
Magnolia Medical Technologies, Inc., inventors of Steripath, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the addition of Joseph Bishop to the executive leadership team as Senior Vice President of Operations and Product Development. ...
Data from the study, “Assessment of a cellular host response test as a sepsis diagnostic for those with suspected infection in the Emergency Department,” showed that Cytovale’s test is a promising tool to aid in the rapid diagnosis and risk stratification for sepsis. ...
The rapid test may aid hospital EDs in saving lives, preventing sepsis-related morbidity, and conserving resources for those who need it most. ...
Data from the study, “Development and validation of a cellular host response test as an early diagnostic for sepsis,” showed that Cytovale’s test has the potential to provide clinically actionable performance in distinguishing potentially septic patients. ...
” “This is an important stage of Inflammatix’s growth as the company advances its first product – the InSep acute infection and sepsis test – towards commercialization and continues development of its deep pipeline. I am excited to join Tim and our talented team as we unleash the power of immune-response testing to ...
The tests are designed to be run on the company’s sample-to-answer, cartridge-based, point-of-care Myrna™ test system, which produces results in under 30 minutes. The funds will enable regulatory clearance and global commercialization of the Myrna system, and the InSep™ acute infection and sepsis test, which is ...